In clinical trials, the antiviral drug Paxlovid cut hospitalization and death rates in high-risk COVID-19 patients by 89%. But some people have struggled to get a prescription due to supply chain bottlenecks and confusion over eligibility. Reset talks to an infectious disease specialist about Paxolovid’s efficacy, and hears from a mom who fought to get the drug for her daughter.
GUESTS: Dr. Robert Murphy, infectious disease specialist with Northwestern University’s Feinberg School of Medicine
Diana Berrent, founder of Survivor Corps